研究技師

---

 

 

EDUCATION AND POSITIONS HELD:

• Ph.D., Chemical Engineering Department of State University of New York at Buffalo, 1990–1996
• Postdoctoral Fellow, Academia Sinica, Taipei, 1996–2001
• Manager of Administrative Office of National Research Program for Genomic Medicine, 2001–2004
• Assistant Research Specialist of Genomic Research Center, Academia Sinica, Taipei, 2004–2007
• Associate Research Specialist of Genomic Research Center, Academia Sinica, Taipei, 2007-2012
• Senior Research Specialist of Genomic Research Center, Academia Sinica, Taipei, 2012-present

FACILITY MANAGEMENT / EXPERTISE:

Structural Function to Drug Discovery

Our research will devote to facilitate technology for probing hot-area that link to specific function in biomolecular recognition and biomolecule-compound interactions, and to devise strategies for structure-based drug discovery as an integral part of the AS-GRC chemical biology research. The major duty, therefore, is to maintain an up-to-date in silico drug discovery platform and to implement new selection methods to assist research PIs in defining features of research targets for drug discovery. Computational approach will be using local surface searching, docking, and fragment-based filling methods, for starting template generation as well as for lead optimization.

研究興趣在致力於開發探測包括:蛋白質、DNA和RNA等生物分子間相互識別，以及生物分子與藥物間相互作用的技術，用以增進發現生物分子連絡特定功能的結構上熱區，結合使用結構為基礎的藥物設計策略，作為中心進行生物化學研究的整合技術。因此主要任務為維繫藥物研發技術平臺，以提供研究人員確定其標的物作為藥物設計目標的特徵。計算方法結合區域性的表面搜查，空間對接，片段底模充填法等技巧，以產生起始模板的結構資訊，以及進行先導藥物最佳化設計。

SELECTED PUBLICATIONS:

• Chuang HC, Liu MF, Wu HY, Wu YT, Cheng TR, Fang JM, 2022, “Photoaffinity labeling of benzophenone-containing salicylanilide compounds to give an insight into the mechanism in disrupting peptidoglycan formation”, BIOORGANIC & MEDICINAL CHEMISTRY, 67, 116819. (SCIE)
• Nicholson MW, Huang CY, Wang JY, Ting CY, Cheng YC, Chan DZH, Lee YC, Hsu CC, Hsu YH, Chang CMC, Hsieh ML, Cheng YY, Lin YL, Chen CH, Wu YT, Hacker TA, Wu JC, Kamp TJ, Hsieh PCH, 2022, “Cardio- and Neurotoxicity of Selected Anti-COVID-19 Drugs”, PHARMACEUTICALS, 15(6), 765. (SCIE)
• Chen WA, Chen YH, Hsieh CY, Hung PF, Chen CW, Chen CH, Lin JL, Cheng TR, Hsu TL, Wu YT, Shen CN, Cheng WC, 2022, “Harnessing natural-product-inspired combinatorial chemistry and computation-guided synthesis to develop N-glycan modulators as anticancer agents”, CHEMICAL SCIENCE, 13(21), 6233-6243. (SCIE)
• Huang CY, Nicholson MW, Wang JY, Ting CY, Tsai MH, Cheng YC, Liu CL, Chan DZH, Lee YC, Hsu CC, Hsu YH, Yang CF, Chang CMC, Ruan SC, Lin PJ, Lin JH, Chen LL, Hsieh ML, Cheng YY, Hsu WT, Lin YL, Chen CH, Hsu YH, Wu YT, Hacker TA, Wu JC, Kamp TJ, Hsieh PCH, 2022, “Population-based high-throughput toxicity screen of human iPSC-derived cardiomyocytes and neurons”, CELL REPORTS, 39(1), 110643. (SCIE)
• Chen SH, Hwang DR, Chen GH, Hsu NS, Wu YT, Li TL, Wong CH, 2012, “Engineering Transaldolase in Pichia stipitis to Improve Bioethanol Production”, ACS CHEMICAL BIOLOGY, 7(3), 481-486. (SCIE)
• Shen YF, Chen YH, Chu SY, Lin MI, Hsu HT, Wu PY, Wu CJ, Liu HW, Lin FY, Lin G, Hsu PH, Yang AS, Cheng YS, Wu YT, Wong CH, Tsai MD, 2011, “E339...R416 salt bridge of nucleoprotein as a feasible target for influenza virus inhibitors”, PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 108, 16515-16520. (SCIE)
• Su CY, Cheng TJ, Lin MI, Wang SY, Huang WI, Lin-Chu SY, Chen YH, Wu CY, Lai MM, Cheng WC, Wu YT, Tsai MD, 2010, “High-throughput identification of compounds targeting influenza RNA-dependent RNA polymerase activity”, PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 107(45), 19151-19156. (SCIE)
• Tu S, Teng YC, Yuan C, Wu YT, Chan MY, Cheng AN, Lin PH, Juan LJ, Tsai MD, 2008, “The ARID domain of the H3K4 demethylase RBP2 binds to a DNA CCGCCC motif”, NATURE STRUCTURAL & MOLECULAR BIOLOGY, 15(4), 419-421. (SCIE)